Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluocortolone. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocortolone. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocortolone. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocortolone. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocortolone. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortolone. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocortolone. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluocortolone. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Fluocortolone. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone. |
| Pegaspargase | The serum concentration of Fluocortolone can be increased when it is combined with Pegaspargase. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortolone. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortolone. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortolone. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortolone. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortolone. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortolone. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortolone. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortolone. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortolone. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortolone. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortolone. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortolone. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortolone. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocortolone. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluocortolone. |
| Cladribine | Fluocortolone may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocortolone. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluocortolone. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocortolone. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluocortolone. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluocortolone. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluocortolone. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocortolone. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluocortolone. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluocortolone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocortolone. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fluocortolone. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluocortolone. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocortolone. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluocortolone. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Fluocortolone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluocortolone. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluocortolone. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluocortolone. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluocortolone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocortolone. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocortolone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocortolone. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Fluocortolone. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocortolone. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluocortolone. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluocortolone. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fluocortolone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Fluocortolone. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fluocortolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocortolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Fluocortolone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluocortolone. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fluocortolone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocortolone. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortolone. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Fluocortolone. |
| Mometasone | The risk or severity of adverse effects can be increased when Mometasone is combined with Fluocortolone. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluocortolone. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluocortolone. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluocortolone. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocortolone. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluocortolone. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocortolone. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluocortolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluocortolone. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocortolone. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluocortolone. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluocortolone. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fluocortolone. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortolone. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Fluocortolone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluocortolone. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluocortolone. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Fluocortolone. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Fluocortolone. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Fluocortolone. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluocortolone. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Fluocortolone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluocortolone. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluocortolone. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Fluocortolone. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Fluocortolone. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluocortolone. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Fluocortolone. |
| Budesonide | The risk or severity of adverse effects can be increased when Budesonide is combined with Fluocortolone. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluocortolone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Fluocortolone. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Fluocortolone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Fluocortolone. |
| Abatacept | The risk or severity of adverse effects can be increased when Abatacept is combined with Fluocortolone. |
| Corticotropin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Fluocortolone. |